BioCentury | Nov 13, 2018
Distillery Therapeutics

Hepatic

...psoriasis, multiple sclerosis and rheumatoid arthritis. Takeda Pharmaceutical Co. Ltd. has the RORγT inverse agonist TAK-828...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Inflammation

...testing the spray-dried dispersion formulation in additional models of inflammation. Takeda Pharmaceutical Co. Ltd. has TAK-828...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Inflammation

...disease, chronic obstructive pulmonary disease (COPD) and various autoimmune diseases. Takeda Pharmaceutical Co. Ltd. has TAK-828...
BioCentury | Jun 9, 2016
Company News

Takeda gets rights to Theravance's GI candidate

...billion) in 2015 sales (see BioCentury, May 30) . Takeda's GI clinical pipeline also includes TAK-828...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

...indications, including cognitive disorders, pain and Alzheimer's disease. In GI, Takeda has just one program: TAK-828...
Items per page:
1 - 5 of 5